Literature DB >> 20616168

Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation.

Jodi M Smith1, Lawrence Corey, Rachel Bittner, Laura S Finn, Patrick J Healey, Connie L Davis, Ruth A McDonald.   

Abstract

The impact of subclinical viral infection on chronic allograft injury in the pediatric renal transplant population is not well defined. We prospectively assessed cytomegalovirus (CMV) and Epstein-Barr virus (EBV) DNAemia by monthly PCR in 55 pediatric renal transplant recipients for the first 2 years after transplantation. Subclinical CMV and EBV infection occurred in 22 and 36%, respectively. Multivariable linear regression analysis suggested that both subclinical CMV and EBV infection independently associate with significant declines in GFR during the first 2 years after transplantation. CMV seronegativity associated with a significantly greater decline in GFR than seropositivity (P < 0.01). Subclinical CMV infection and subclinical EBV infection each associated with approximately fourfold greater odds of histologic evidence of chronic allograft injury (odds ratio 4.61 [95% confidence interval 1.18 to 18.07] and odds ratio 4.33 [95% confidence interval 1.34 to 14.00], respectively). An increase in viral load of CMV or EBV also associated with increased risk for moderate to severe chronic allograft injury. Taken together, these results demonstrate an association between subclinical CMV and EBV infections, which occur despite standard antiviral prophylaxis, and chronic allograft injury in pediatric renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616168      PMCID: PMC3013517          DOI: 10.1681/ASN.2009111188

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  33 in total

1.  Calibration curves for real-time PCR.

Authors:  K Kay-Yin Lai; Linda Cook; Elizabeth M Krantz; Lawrence Corey; Keith R Jerome
Journal:  Clin Chem       Date:  2005-07       Impact factor: 8.327

2.  Banff 07 classification of renal allograft pathology: updates and future directions.

Authors:  K Solez; R B Colvin; L C Racusen; M Haas; B Sis; M Mengel; P F Halloran; W Baldwin; G Banfi; A B Collins; F Cosio; D S R David; C Drachenberg; G Einecke; A B Fogo; I W Gibson; D Glotz; S S Iskandar; E Kraus; E Lerut; R B Mannon; M Mihatsch; B J Nankivell; V Nickeleit; J C Papadimitriou; P Randhawa; H Regele; K Renaudin; I Roberts; D Seron; R N Smith; M Valente
Journal:  Am J Transplant       Date:  2008-02-19       Impact factor: 8.086

3.  Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.

Authors:  Elfriede Ruttmann; Christian Geltner; Brigitte Bucher; Hanno Ulmer; Daniel Höfer; Herbert B Hangler; Severin Semsroth; Raimund Margreiter; Günther Laufer; Ludwig C Müller
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

4.  Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.

Authors:  K A Newell; E M Alonso; P F Whitington; D S Bruce; J M Millis; J B Piper; E S Woodle; S M Kelly; H Koeppen; J Hart; C M Rubin; J R Thistlethwaite
Journal:  Transplantation       Date:  1996-08-15       Impact factor: 4.939

5.  American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation.

Authors:  A Humar; M Michaels
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

6.  Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.

Authors:  Luciano Potena; Cecile T J Holweg; Clifford Chin; Helen Luikart; Dana Weisshaar; Balasubramanian Narasimhan; William F Fearon; David B Lewis; John P Cooke; Edward S Mocarski; Hannah A Valantine
Journal:  Transplantation       Date:  2006-08-15       Impact factor: 4.939

7.  Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation.

Authors:  Li Li; Abanti Chaudhuri; Lauren A Weintraub; Frank Hsieh; Sheryl Shah; Steven Alexander; Oscar Salvatierra; Minnie M Sarwal
Journal:  Pediatr Transplant       Date:  2007-03

8.  Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.

Authors:  S M Cockfield; J K Preiksaitis; L D Jewell; N A Parfrey
Journal:  Transplantation       Date:  1993-07       Impact factor: 4.939

9.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.

Authors:  Jodi M Smith; Lawrence Corey; Patrick J Healey; Connie L Davis; Ruth A McDonald
Journal:  Transplantation       Date:  2007-06-15       Impact factor: 4.939

View more
  25 in total

1.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

Review 2.  Viral surveillance and subclinical viral infection in pediatric kidney transplantation.

Authors:  Jodi M Smith; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2014-08-16       Impact factor: 3.714

3.  Cytomegalovirus and anemia: not just for transplant anymore.

Authors:  Michael E Seifert; Daniel C Brennan
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

4.  The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.

Authors:  Priya S Verghese; David O Schmeling; Jennifer A Knight; Arthur J Matas; Henry H Balfour
Journal:  Transplantation       Date:  2015-03       Impact factor: 4.939

5.  Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation.

Authors:  R Ettenger; H Chin; K Kesler; N Bridges; P Grimm; E F Reed; M Sarwal; R Sibley; E Tsai; B Warshaw; A D Kirk
Journal:  Am J Transplant       Date:  2017-02-01       Impact factor: 8.086

Review 6.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 7.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

8.  Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.

Authors:  Tomas Reischig; Petra Hribova; Pavel Jindra; Ondrej Hes; Mirko Bouda; Vladislav Treska; Ondrej Viklicky
Journal:  J Am Soc Nephrol       Date:  2012-08-23       Impact factor: 10.121

9.  Prospective Assessment of Adenovirus Infection in Pediatric Kidney Transplant Recipients.

Authors:  Rachel M Engen; Meei-Li Huang; Giulia E Park; Jodi M Smith; Ajit P Limaye
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

10.  Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions.

Authors:  Thomas Bachelet; Lionel Couzi; Vincent Pitard; Xavier Sicard; Claire Rigothier; Sébastien Lepreux; Jean-François Moreau; Jean-Luc Taupin; Pierre Merville; Julie Déchanet-Merville
Journal:  J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.